Ingalls & Snyder LLC’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,255
| Closed | -$139K | – | 447 |
|
|
2022
Q3 | $139K | Sell |
2,255
-500
| -18% | -$31.5K | 0.01% | 402 |
|
|
2022
Q2 | $170K | Sell |
2,755
-1,000
| -27% | -$61.9K | 0.01% | 413 |
|
|
2022
Q1 | $223K | Hold |
3,755
| – | – | 0.01% | 422 |
|
|
2021
Q4 | $273K | Sell |
3,755
-1,150
| -23% | -$79.2K | 0.01% | 394 |
|
|
2021
Q3 | $343K | Hold |
4,905
| – | – | 0.02% | 363 |
|
|
2021
Q2 | $338K | Sell |
4,905
-439
| -8% | -$29.3K | 0.02% | 367 |
|
|
2021
Q1 | $345K | Sell |
5,344
-203
| -4% | -$13.1K | 0.02% | 343 |
|
|
2020
Q4 | $323K | Sell |
5,547
-1,925
| -26% | -$116K | 0.02% | 336 |
|
|
2020
Q3 | $472K | Buy |
7,472
+4,809
| +181% | +$333K | 0.03% | 248 |
|
|
2020
Q2 | $205K | Sell |
2,663
-97
| -4% | -$7.43K | 0.01% | 366 |
|
|
2020
Q1 | $206K | Sell |
2,760
-500
| -15% | -$34.5K | 0.01% | 366 |
|
|
2019
Q4 | $212K | Sell |
3,260
-400
| -11% | -$26K | 0.01% | 370 |
|
|
2019
Q3 | $232K | Sell |
3,660
-5
| -0.1% | -$327 | 0.01% | 379 |
|
|
2019
Q2 | $248K | Sell |
3,665
-123,563
| -97% | -$8.13M | 0.01% | 375 |
|
|
2019
Q1 | $8.27M | Sell |
127,228
-459
| -0.4% | -$30.5K | 0.39% | 65 |
|
|
2018
Q4 | $7.99M | Sell |
127,687
-7,887
| -6% | -$551K | 0.42% | 61 |
|
|
2018
Q3 | $10.5M | Sell |
135,574
-575
| -0.4% | -$43.4K | 0.44% | 61 |
|
|
2018
Q2 | $9.64M | Sell |
136,149
-6,384
| -4% | -$451K | 0.45% | 62 |
|
|
2018
Q1 | $10.7M | Sell |
142,533
-38,697
| -21% | -$3.08M | 0.52% | 54 |
|
|
2017
Q4 | $13M | Buy |
+181,230
| New | +$13.8M | 0.6% | 45 |
|
|
2017
Q3 | – | Sell |
-181,494
| Closed | -$12.8M | – | 372 |
|
|
2017
Q2 | $12.8M | Sell |
181,494
-578
| -0.3% | -$38.5K | 0.7% | 40 |
|
|
2017
Q1 | $12.4M | Buy |
182,072
+26,332
| +17% | +$1.85M | 0.66% | 40 |
|
|
2016
Q4 | $11.2M | Sell |
155,740
-15,278
| -9% | -$1.14M | 0.61% | 41 |
|
|
2016
Q3 | $13.5M | Buy |
171,018
+8,877
| +5% | +$721K | 0.75% | 35 |
|
|
2016
Q2 | $13.5M | Buy |
162,141
+2,834
| +2% | +$252K | 0.8% | 33 |
|
|
2016
Q1 | $14.6M | Sell |
159,307
-2,581
| -2% | -$233K | 0.93% | 33 |
|
|
2015
Q4 | $16.4M | Sell |
161,888
-4,442
| -3% | -$462K | 1.05% | 26 |
|
|
2015
Q3 | $16.3M | Buy |
166,330
+6,217
| +4% | +$690K | 1.07% | 24 |
|
|
2015
Q2 | $18.7M | Sell |
160,113
-1,412
| -0.9% | -$154K | 1.03% | 25 |
|
|
2015
Q1 | $15.8M | Buy |
161,525
+95,292
| +144% | +$9.68M | 0.87% | 31 |
|
|
2014
Q4 | $6.24M | Buy |
66,233
+58,600
| +768% | +$6.06M | 0.36% | 61 |
|
|
2014
Q3 | $812K | Buy |
7,633
+420
| +6% | +$41.1K | 0.04% | 194 |
|
|
2014
Q2 | $598K | Buy |
+7,213
| New | +$561K | 0.03% | 228 |
|
Other funds holding GILD
Ingalls & Snyder LLC's GILD Position: Q4 2022 in Review
Ingalls & Snyder LLC sold out of Gilead Sciences (GILD) in Q4 2022, closing a stake of 2,255 shares — an estimated $139K sold.
Ingalls & Snyder LLC first reported a position in GILD in Q2 2014 and held it in 33 quarters. The position peaked at $18.7M in Q2 2015. 1,767 funds tracked by Wall St. Rank hold GILD as of Q4 2022.
- Ingalls & Snyder LLC reported no remaining Gilead Sciences position as of Q4 2022 after selling out during the quarter.
- Ingalls & Snyder LLC sold 2,255 Gilead Sciences shares in Q4 2022, an estimated $139K.
- Ingalls & Snyder LLC first reported a position in Gilead Sciences in Q2 2014 and held it in 33 quarters.
- Ingalls & Snyder LLC's Gilead Sciences position peaked at $18.7M in Q2 2015.
- 1,767 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2022.
Based on Ingalls & Snyder LLC's 13F filing for Q4 2022, filed 31 Jan 2023.